SeaStar Medical Holding Corporation (ICU)
| Market Cap | 27.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.67M |
| Shares Out | 3.11M |
| EPS (ttm) | -25.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 217,851 |
| Open | 9.55 |
| Previous Close | 9.34 |
| Day's Range | 8.34 - 9.60 |
| 52-Week Range | 3.25 - 42.93 |
| Beta | -1.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2024 |
About ICU
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquarter... [Read more]
Financial Performance
Financial StatementsNews
SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors, Je...
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical's Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...
SeaStar Medical Announces 25-for-1 Reverse Stock Split
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical's Selective Cytopheretic Device Who Achieved Transplant Eligibility
SCD's ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such investors...
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solu...
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of h...
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercia...
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company...
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
March 13 webcast showcasing Quelimmune ™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com
Manuscript Discussing the Benefit of SeaStar Medical's Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure
Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical's Selective Cytopheretic Device for Pediatric Acute Kidney Injury
SCD-PED (Pediatric) is the first FDA-approved product in the Company's Quelimmune™ product family
ICU stock price: Here's why SeaStar Medical shares have surged
SeaStar Medical Holding (NASDAQ: ICU) stock price has done well this year even as the company continued diluting its shareholders. The stock is about to hit $1, meaning that it has surged by more than...
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology
DENVER, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Appoints David A. Green as Chief Financial Officer
DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
DENVER, Dec. 28, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts
DENVER, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune...
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce th...
FDA Issues Approvable Letter for SeaStar Medical's Selective Cytopheretic Device for Pediatric Patients
DENVER, Oct. 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune...
SeaStar Medical's stock more than doubles in 2 days to get back above the $1 level
Shares of SeaStar Medical Holding Corp. ICU, +70.05% rocketed 45.3% on heavy volume in premarket trading Thursday, to take them back above the $1 mark for the first time in five months. Trading volume...